How to approach patients who are MRD positive after initial induction chemotherapy?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke with Jonathan Canaani, Weill Cornell Medicine, New York, US. We asked, How to approach patients who are measurable residual disease positive after initial induction chemotherapy?

Firstly, Canaani highlights current treatment options for patients with acute myeloid leukemia who are measurable residual disease positive following initial induction chemotherapy. Then, he provides an overview of the UK AML18 trial (NCT02272478) and discusses the potential benefit of intensifying chemotherapy in older patients with acute myeloid leukemia who remain measurable residual disease positive after initial induction chemotherapy. Canaani concludes by raising the need for future randomized clinical trials to determine the best approach for this patient population.